Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma, Novartis, Roche, Biohaven Pharmaceuticals, Scholar Rock, AnnJi Pharmaceutical

New York, USA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma, Novartis, Roche, Biohaven Pharmaceuticals, Scholar Rock, AnnJi Pharmaceutical

The dynamics of the spinal muscular atrophy market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.

DelveInsight’s Spinal Muscular Atrophy Market Insights report includes a comprehensive understanding of current treatment practices, spinal muscular atrophy emerging drugs, market share of individual therapies, and current and forecasted spinal muscular atrophy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Spinal Muscular Atrophy Market Report

• As per DelveInsight’s analysis, the spinal muscular atrophy market is anticipated to grow at a significant CAGR by 2032.
• As per Delveinsight’s analysis, the total prevalent population of SMA in the 7MM was around 20K cases in 2020, out of which the United States accounted for nearly 13K cases in 2020. 
• Leading spinal muscular atrophy companies such as Biogen, NMD Pharma A/S, Novartis Pharmaceuticals, Hoffmann-La Roche, Biohaven Pharmaceuticals, Inc., Scholar Rock, Inc., AnnJi Pharmaceutical Co., Ltd., and others are developing novel spinal muscular atrophy drugs that can be available in the spinal muscular atrophy market in the coming years.
• Some of the key therapies for spinal muscular atrophy treatment include Nusinersen, NMD670, OAV101, Risdiplam, Taldefgrobep alfa, SRK-015, AJ201, and others. 
• The FDA Office of Orphan Products Development granted GYM329 Orphan Drug Designation for the treatment of patients with SMA in December 2021.
•  The US FDA has granted orphan drug designation and the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of SMA.

Discover which therapies are expected to grab the major spinal muscular atrophy market share @ Spinal Muscular Atrophy Market Report

Spinal Muscular Atrophy Overview

Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that follows an autosomal recessive inheritance pattern. It is characterized by progressive muscle wasting resulting from the degeneration of motor neurons in the anterior horn of the spinal cord, which controls voluntary muscle movement. SMA is a leading cause of infant mortality and mobility impairment, primarily affecting proximal and respiratory muscles. The most prevalent form of SMA is referred to as ‘5q SMA’ due to its genetic origin. The severity of symptoms can vary widely depending on the type of SMA and its onset. In general, individuals with SMA may experience muscle weakness, muscle atrophy (shrinkage), and decreased motor function. Common symptoms include difficulty with tasks like crawling, walking, and lifting objects. In more severe cases, SMA can lead to respiratory difficulties, difficulty swallowing, and compromised overall mobility. SMA diagnosis typically involves a physical examination, family history assessment, and a range of diagnostic tests, including creatine kinase (CK) level testing, muscle biopsy, prenatal testing, newborn screening, among others.

Spinal Muscular Atrophy Epidemiology Segmentation

The spinal muscular atrophy epidemiology section provides insights into the historical and current spinal muscular atrophy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The spinal muscular atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Spinal Muscular Atrophy Prevalent Cases 
• Spinal Muscular Atrophy Type-specific Prevalent Cases 
• Spinal Muscular Atrophy Age-specific Prevalent Cases 

Download the report to understand which factors are driving spinal muscular atrophy epidemiology trends @ Spinal Muscular Atrophy Epidemiological Insights

Spinal Muscular Atrophy Treatment Market 

The introduction of three approved therapies for SMA (Spinraza, Evrysdi, and Zolgensma, a gene therapy) has addressed several unmet needs in SMA treatment. Additionally, managing SMA involves a comprehensive approach that includes supportive and multidisciplinary care aimed at minimizing complications and enhancing the quality of life. The current market also offers options for symptomatic relief. Furthermore, SMA management strategies encompass aspects such as nutrition, respiratory care assessment, addressing respiratory muscle weakness, orthopedic care, rehabilitation, and the use of some off-label medications.

Novartis’ Zolgensma, an adeno-associated virus vector-based gene therapy, is prescribed for the treatment of spinal muscular atrophy in children under 2 years old with bi-allelic SMN1 gene mutations. The primary goal of this therapy is to introduce a functional human SMN gene into targeted motor neuron cells, thereby stimulating the production of sufficient SMN protein to enhance motor neuron function and maintain consistent protein expression.

Evrysdi, developed by Hoffmann-La Roche, is a splicing modifier targeting survival motor neuron 2 (SMN2). This medication is prescribed for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older, offering the convenience of daily administration by mouth or feeding tube in a home setting. It is a breakthrough therapy for SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency.

Biogen’s drug Spinraza has gained approval for the treatment of spinal muscular atrophy (SMA) in both pediatric and adult patients. Nusinersen serves as the active ingredient within this medication. It’s worth noting that Nusinersen is a modified oligonucleotide, where the 2’-hydroxyl groups of the ribofuranosyl rings have been replaced by 2’-O-2-methoxyethyl groups, and the phosphate linkages have been substituted with phosphorothioate linkages. The specific target of Nusinersen is the intronic splicing silencer N1 (ISS-N1) found in exon 7 of the SMN2 transcript.

Learn more about the FDA-approved drugs for spinal muscular atrophy @ Drugs for Spinal Muscular Atrophy Treatment 

Key Spinal Muscular Atrophy Therapies and Companies

• Nusinersen: Biogen
• NMD670: NMD Pharma A/S
• OAV101: Novartis Pharmaceuticals
• Risdiplam: Hoffmann-La Roche
• Taldefgrobep alfa: Biohaven Pharmaceuticals, Inc.
• SRK-015: Scholar Rock, Inc.
• AJ201: AnnJi Pharmaceutical Co., Ltd.

To know more about spinal muscular atrophy clinical trials, visit @ Spinal Muscular Atrophy Treatment Drugs 

Spinal Muscular Atrophy Market Dynamics

The spinal muscular atrophy market dynamics are anticipated to change in the coming years. Presently, there exist three FDA-approved treatments for spinal muscular atrophy: Spinraza, Evrysdi, and Zolgensma. Among these options, Zolgensma stands out as a life-saving gene therapy that has gained approval in various international markets known as the 7MM. Evrysdi represents an orally administered SMA medication, offering the convenience of at-home treatment and potentially being a preferred choice over Spinraza, which requires intrathecal administration. Currently, there are promising SMA drugs in mid- and early-phase development, spearheaded by Roche, Scholar Rock, and Cytokinetics. It is imperative for other pharmaceutical companies to contribute to the development of therapies that cater to the diagnostic and medical requirements of less common SMA variants, given the significant market potential.

However, several factors may impede the growth of the spinal muscular atrophy market. Research indicates that some SMA patients treated with the gene therapy Zolgensma may require additional treatment, as not all motor neurons are effectively transduced by the gene therapy, leaving certain neurons untreated. Unfortunately, the high cost of Zolgensma makes it nearly unaffordable for the general population. Furthermore, the annual expenses associated with Spinraza and Evrysdi therapy are also significantly elevated, placing a heavy financial burden on patients.

Scope of the Spinal Muscular Atrophy Market Report

• Therapeutic Assessment: Spinal Muscular Atrophy current marketed and emerging therapies
• Spinal Muscular Atrophy Market Dynamics: Attribute Analysis of Emerging Spinal Muscular Atrophy Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Spinal Muscular Atrophy Market Access and Reimbursement

Discover more about spinal muscular atrophy drugs in development @ Spinal Muscular Atrophy Clinical Trials

Table of Contents

Related Reports

Spinal Muscular Atrophy Epidemiology Forecast

Spinal Muscular Atrophy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted spinal muscular atrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Spinal Muscular Atrophy Pipeline

Spinal Muscular Atrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key spinal muscular atrophy companies, including Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics,  among others.

Duchenne Muscular Dystrophy Pipeline

Duchenne Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Duchenne muscular dystrophy companies, including Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutics,  among others.

Becker Muscular Dystrophy Pipeline

Becker Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key becker muscular dystrophy companies, including Epirium Bio, Ultragenyx, Strykagen, among others.

Facioscapulohumeral Muscular Dystrophy PIpeline

Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key facioscapulohumeral muscular dystrophy companies, including miRecule, Arrowhead Pharmaceuticals, Fulcrum Therapeutics, among others.

Other Trending Reports

Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter